Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AnifAPS
2025-520918-64-00Phase 2Authorised
- Sponsor
- National and Kapodistrian University of Athens
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anifrolumab in antiphospholipid syndrome (APS), sponsored by National and Kapodistrian University of Athens. Primary endpoint: Incidence of adverse events and adverse events of special interest. Planned start Oct 2025; status: authorised.
02
Drugs
anifrolumab
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on 2025-520918-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520918-64-00.